Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IVIb · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| IVIb | DRUG | 800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8 |
Inclusion Criteria: * Healthy volunteers between the ages of 18 and 65 years (at the time of consent). Exclusion Criteria: * Participants lacking good venous access in both arms. * History of allergy or hypersensitivity to NSAIDs or any component of intravenous ibuprofen. * Have never taken aspir...
IVIb is an investigational small molecule drug being developed by Cumberland Pharmaceuticals Inc. (CPIX). It is currently in Phase 1 clinical development. The drug is being studied for use in healthy subjects, according to clinical trial data.
IVIb is being studied for use in healthy subjects. It is currently in Phase 1 clinical development, with a completed pharmacokinetic study in healthy adult volunteers. The drug's specific therapeutic indication has not been established beyond this early-stage research.
IVIb is being developed by Cumberland Pharmaceuticals Inc., a company traded on the NASDAQ under the ticker symbol CPIX. The company is conducting clinical trials to evaluate the drug's pharmacokinetics in healthy subjects.
IVIb is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a pharmacokinetic study in healthy adult subjects. The drug is still investigational and has not been approved for any use.
IVIb has one completed clinical trial, NCT00867880, titled "Pharmacokinetic Study Of Ibuprofen Injection (IVIb) In Healthy Adult Subjects." This Phase 1 study enrolled 12 healthy volunteers in Australia and was completed.